CAI
Caris Life Sciences, Inc.
Key Financials
Revenue
$812.0M
↑ 97.0%
Net Income
$-68088000
↑ 75.8%
Operating Income
$45.1M
↑ 117.5%
EPS (Diluted)
$-3.22
↑ 69.8%
Total Liabilities
$548.4M
↓ 11.7%
Total Assets
$1.1B
↑ 227.5%
Long-term Debt
$378.4M
↑ 1.4%
Shareholders' Equity
$577.3M
↑ 123.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/23/2026 | View on SEC |
| 144 | 9/22/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| 144 | 9/17/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 144 | 9/4/2026 | View on SEC |
| 144 | 9/3/2026 | View on SEC |
| 144 | 8/24/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CAI |
| Company Name | Caris Life Sciences, Inc. |
| CIK | 2019410 |
| Sector | Services-Medical Laboratories |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | TX |
| Phone | (866) 771-8946 |